Európska únia - čeština - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - psi - pro léčbu non-resekabilním, non-metastatický (kdo staging) podkožní mastocytů se nachází na nebo distální k lokti, nebo hleznu, a non-resekabilním, non metastazující kožní žírných buněk nádory u psů.

Európska únia - čeština - EMA (European Medicines Agency)

dechra regulatory b.v. - mirtazapin - psychoanaleptics, antidepressants in combination with psycholeptics - kočky - pro tělesné hmotnosti u koček dochází nechutenství a ztráta hmotnosti, vyplývající z chronické zdravotní podmínky.

Európska únia - čeština - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - infekce dýchacích cest - antibakteriální látky pro systémové použití, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

Európska únia - čeština - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplasmy prsů - antineoplastická činidla - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Európska únia - čeština - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Európska únia - čeština - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin-dihydrochloridu - fenylketonurie - jiné zažívací trakt a produkty metabolismu, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Európska únia - čeština - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinsonova choroba - antiparkinsonické léky - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Česká republika - čeština - Adama

adama - emulgovatelný koncentrát - cyprodinil + isopyrazam - fungicidy

Európska únia - čeština - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi s.r.o., praha array - 27 alanin; 96 arginin; 55 glycin; 717 histidin; 790 isoleucin; 829 leucin; 4566 lysin-acetÁt; 2445 methionin; 1117 fenylalanin; 4147 prolin; 4717 serin; 1418 taurin; 1459 threonin; 1503 tryptofan; 1507 tyrosin; 1514 valin; 5599 dihydrÁt chloridu vÁpenatÉho; 16396 natrium-glycerofosfÁt; 864 heptahydrÁt sÍranu hoŘeČnatÉho; 1174 chlorid draselnÝ; 1306 trihydrÁt natrium-acetÁtu; 4957 monohydrÁt glukosy - infuzní roztok - roztoky pro parenterÁlnÍ vÝŽivu, kombinace